Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.
about
Hepatocellular carcinoma and hepatitis B surface proteinAnti-HDV IgM as a marker of disease activity in hepatitis deltaHepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B.HIV and co-infections.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analoguesTreatment options for hepatitis delta virus infection.Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare.Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients.HBsAg seroclearance with NUCs: rare but important.The role of HBsAg levels in the current management of chronic HBV infection.A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy.Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapyPatients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational studyViral Biomarkers in Chronic HBeAg Negative HBV Infection
P2860
Q26766123-D1188EEF-4B11-4A14-BD34-CD9E2F70F90EQ28541284-A00F9153-C4AA-41A3-9EEE-9E82C003A367Q34384793-67CD1EC5-5379-4525-87CF-9A02357D0C31Q34612816-1D78B299-AC9A-4B3A-AC15-429DB750316AQ36970184-B7A92198-237B-44AB-9BEA-60C8CE6648A0Q38224440-583F13E1-ACE5-4B1D-B1EB-9C16720E0FE2Q39502937-F89FE8B8-485C-4BEB-80EE-CD91FFA8BA57Q40073140-9A7DD280-74EA-4447-B32F-4347ED399A8EQ40160001-9430F4A7-1B07-46BE-BB6B-B29DACBF7396Q40189344-09EF3FFC-4F01-405A-AD55-E2C27CC20451Q40272794-0886F386-81FC-424C-98A4-7847B17FB1E8Q40324314-81AEC6D9-6114-4CAE-B417-D7A3D2BD00A0Q40769626-E4B79375-510B-4955-BC19-82FC1EB1DB3AQ41121379-01B9017A-2BC0-4C8D-91D0-64B134EB3395Q41719578-D7571446-5746-4450-AFA4-F1327065C3C5Q42244677-FBCDB0CC-E2DD-4423-9A79-5196CCB2CADCQ42360905-940165CC-BA8C-4EB8-B9C8-318D6CE6DAB4Q44766209-A4C2B1B8-D681-48A1-9303-6FC0440BC603Q47105045-91A757FE-F4DF-4DAE-958A-52BE491EE229Q47153893-1C617B08-8EEF-4835-967C-04E2695514E5Q54217690-197A4553-F283-4203-AD9C-2EF7527A0FB7Q58235736-2CE566B3-DA89-475A-8CDF-7EE73DB9A133Q58704580-E93CCCC1-C615-4AE9-A008-FC7882A380DFQ59126856-73089D70-BEB0-49FF-B1E9-5AFC9BB41269
P2860
Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Hepatitis B surface antigen (H ...... cleoside/nucleotide analogues.
@en
type
label
Hepatitis B surface antigen (H ...... cleoside/nucleotide analogues.
@en
prefLabel
Hepatitis B surface antigen (H ...... cleoside/nucleotide analogues.
@en
P2093
P50
P356
P1433
P1476
Hepatitis B surface antigen (H ...... ucleoside/nucleotide analogues
@en
P2093
Antoaneta Markova
Hans L Tillmann
Heiner Wedemeyer
Karsten Wursthorn
Katja Deterding
Michael P Manns
Sandra Schulz
P304
P356
10.3851/IMP1866
P577
2011-01-01T00:00:00Z